Why the study?
Does decreased estimated GFR increase the risk of mortality due to ischaemic heart disease in hypertensive patients?
Does decreased estimated GFR increase the risk of mortality due to ischaemic heart disease in hypertensive patients?
Answers are grounded in this paper and cite their sources.
Decreased estimated GFR is an independent predictor of increased mortality due to ischaemic heart disease in hypertensive patients, emphasizing the need for integrated cardiovascular and renal protection.
During recent years, numerous studies have demonstrated the existence of a close relationship between alterations in renal function and a significant increase in cardiovascular risk in different clinical situations. The relationship appears to be particularly relevant in the hypertensive population due to the high prevalence of arterial hypertension in the general population and the frequent finding of alterations of renal function in individuals with elevated values of blood pressure [1]. Analysis of the alterations of renal function in different series of patients with arterial hypertension shows that the higher the global cardiovascular risk in a given hypertensive patient, the higher the possibility of finding the simultaneous presence of a deranged renal function [2]. In this issue of the journal, Hailpern et al. [3] report data obtained in a large cohort of essential hypertensive patients that reveal a significant inverse correlation between values of estimated glomerular filtration rate (GFR) at baseline and mortality due to ischaemic heart disease (IHD) during follow-up. Such a relationship persisted after adjustement for all known cardiovascular risk factors, and an increase of 33% in risk for mortality due to IHD was observed for each reduction in estimated GFR of 10 ml/min per 1.73 m2. These data emphasize the need to estimate renal function (serum creatinine, estimated GFR or creatinine clearance and albuminuria) in every hypertensive patient to correctly stratify an individual's global cardiovascular risk in agreement with recently published guidelines for the evaluation and treatment of arterial hypertension [4,5]. The finding of a confirmed value of estimated GFR or creatinine clearance below 60 ml/min, at baseline or during follow-up, for a given hypertensive patient allows their inclusion in the group classified as being of high cardiovascular risk [4,6]. This risk can be increased independently by the presence of albuminuria (either micro or macro) and left ventricular hypertrophy being more frequent in those patients presenting with values below 60 ml/min [7,8]. According to this classification, patients with estimated GFR or creatinine clearance values below 60 ml/min, require strict control of blood pressure to values below 130/80 mmHg, or even lower if albuminuria above 1 g is present [4,5]. However, the guidelines provide little information about the combination of antihypertensive drugs usually required to attain this control. The need to use an angiotensin-converting enzyme inhibitor or an angiotensin II receptor blocker in this combination is generally considered in those patients presenting with albuminuria [4,5]. Recent data appear to indicate that cardiovascular risk and renal protection are attained simultaneously if a drug counteracting the effects of angiotensin II is used in these patients, even in the absence of albuminuria [4,9,10]. The addition of a statin and aspirin (once control of blood pressure is attained) must also be considered due to the level of global cardiovascular risk in these patients. In this sense, the addition of a statin to patients with IHD has been shown to prevent the decline in renal function with time [11] and to reduce cardiovascular events when renal function is moderately diminished [12]. The protective effects of aspirin for the prevention of myocardial infarction, as observed in the HOT study, were particularly prevalent in those patients presenting an elevated value of serum creatinine at baseline [13]. Recent data have confirmed the efficacy and safety of low-dose aspirin in patients with chronic kidney disease [14]. Another recent approach to improve the cardiovascular risk and renal prognosis of these patients consists of the correction of anaemia if present [15]. Last, but not least, it is necessary to insist that patients quit smoking because tobacco has been shown to be an independent risk factor for the progression of renal failure, as well as cardiovascular disease [15]. In summary, the finding of a diminished estimated GFR or creatinine clearance emphasizes the need for an integrated therapeutic approach to obtain the best simultaneous protection of the cardiovascular and renal systems in the hypertensive population.
No takes yet. Share an insight, caveat, or question.
Luís M. Ruilope (2005) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: